Skip to main content

Trabedersen

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

  • RegistryNCT06579196
  • PhasePhase 1/2
  • StatusActive Not Recruiting
  • ConditionNon-small Cell Lung Cancer
  • SponsorUniversity of Nebraska
How Trabedersen worksNCT065791961 min

What the film says

Read the transcript

Lung cancer is America's leading cancer killer. When tumors carry the marker PD-L1, treatment now starts with pembrolizumab, which takes the brakes off the immune system. It helps some; most tumors find a way through.

One way is a molecule called TGF-beta two, which tumors pour out to tell immune cells to stand down.

The idea: cut off that molecule while pembrolizumab does its work.

Trabedersen is a short strand of synthetic DNA that binds the instructions for TGF-beta two so they cannot be read. It has been tried before, in pancreatic cancer and glioma.

This trial, at the University of Nebraska with Omar Abughanimeh, gives it by infusion with pembrolizumab, and asks first what dose is safe. Public record; not medical advice.

Sources behind this film

Show 4 more sources

The drug

What is being tested.

Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).

Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.

The main question(s) it aims to answer are: * What medical problems to participants have when taking OT101 together with Pembrolizumab? * What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combination therapy? * Does the combination therapy delay progression or relapse of the participants Non-Small Cell Lung Cancer? Participants will: * Receive intravenous OT-101/Trabedersen for 4 days once every 2 weeks.

The study

How the trial runs.

The goal of this clinical trial is to: 1) evaluate the safety and recommended dose of the drug OT-101/Trabedersen when combined with Pembrolizumab and 2) determine the efficacy of the combination therapy in adults with certain types of Non-Small Cell Lung Cancer.

The main question(s) it aims to answer are: * What medical problems to participants have when taking OT101 together with Pembrolizumab? * What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combination therapy? * Does the combination therapy delay progression or relapse of the participant's Non-Small Cell Lung Cancer? Participants will: * Receive intravenous OT-101/Trabedersen for 4 days once every 2 weeks.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically/cytologically proven diagnosis of non-small cell lung cancer (NSCLC) with a PD-L1 of at least 1%
  • Metastatic disease or disease not amenable for curative intent therapy
  • No prior treatment for metastatic NSCLC. Early-stage disease therapy acceptable if completed at least six months prior and did not include immunotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Measurable disease by RECIST criteria
  • Adequate organ and marrow function as defined below:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.